These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 12435166)

  • 1. Expanding role of biologic agents in rheumatoid arthritis.
    Kalden JR
    J Rheumatol Suppl; 2002 Nov; 66():27-37. PubMed ID: 12435166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of biologicals in early rheumatoid arthritis.
    Haque UJ; Bathon JM
    Best Pract Res Clin Rheumatol; 2005 Feb; 19(1):179-89. PubMed ID: 15588978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rheumatoid arthritis initial therapy: unanswered questions.
    O'Dell J
    J Rheumatol Suppl; 2005 Jan; 72():14-6. PubMed ID: 15660457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
    Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
    Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy.
    Yazici Y; Shi N; John A
    Bull NYU Hosp Jt Dis; 2008; 66(2):77-85. PubMed ID: 18537774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis.
    Haraoui B
    J Rheumatol Suppl; 2005 Jan; 72():46-7. PubMed ID: 15660467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
    Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA;
    Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
    Sesin CA; Bingham CO
    Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From aspirin to biologics: therapeutic implications for rheumatoid arthritis.
    Wright V
    J Rheumatol Suppl; 1992 Jan; 32():95-7. PubMed ID: 1613740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a need for new therapies for rheumatoid arthritis?
    Fleischmann RM
    J Rheumatol Suppl; 2005 Feb; 73():3-7; discussion 29-30. PubMed ID: 15693109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Starting a disease modifying antirheumatic drug or a biologic agent in rheumatoid arthritis: standards of practice for RA treatment.
    Wolfe F; Rehman Q; Lane NE; Kremer J
    J Rheumatol; 2001 Jul; 28(7):1704-11. PubMed ID: 11469485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment and management of rheumatoid arthritis.
    Haraoui B
    J Rheumatol Suppl; 2009 Jun; 82():2-10. PubMed ID: 19509324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: where the rubber meets the road.
    Bathon JM; Cohen SB
    Arthritis Rheum; 2008 Jun; 59(6):757-9. PubMed ID: 18512712
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of prognostic markets to guide biologic therapies for rheumatoid arthritis.
    D'Arcy CA; Willkens RF
    J Rheumatol; 2002 Dec; 29(12):2662; author reply 2662-3. PubMed ID: 12465172
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic strategies in early rheumatoid arthritis.
    Smolen JS; Aletaha D; Machold KP
    Best Pract Res Clin Rheumatol; 2005 Feb; 19(1):163-77. PubMed ID: 15588977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Prosorba column apheresis in patients with chronic refractory rheumatoid arthritis.
    Roth S
    J Rheumatol; 2004 Nov; 31(11):2131-5. PubMed ID: 15517623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunopathogenesis and treatment of rheumatoid arthritis.
    Lipsky PE
    J Rheumatol Suppl; 1992 Jan; 32():92-4. PubMed ID: 1613739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative overview of safety of the biologics in rheumatoid arthritis.
    Khraishi M
    J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of early rheumatoid arthritis in developing countries. Biologics or disease-modifying anti-rheumatic drugs?
    Yen JH
    Biomed Pharmacother; 2006 Dec; 60(10):688-92. PubMed ID: 17049202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.